<DOC>
	<DOCNO>NCT01017653</DOCNO>
	<brief_summary>This phase II study combination panitumumab irinotecan malignant glioma patient . The primary objective study determine activity combination panitumumab irinotecan measure 6-month progression-free survival . Secondary objective include following- determine safety panitumumab combination irinotecan patient malignant glioma ; determine effect panitumumab combination irinotecan corticosteroid dose patient ; explore relationship epidermal growth factor receptor ( EGF-R ) mutational analysis efficacy toxicity ; , determine response rate overall survival recurrent glioblastoma ( GBM ) patient treat panitumumab combination irinotecan . The patient histologically document grade 4 malignant glioma ( glioblastoma multiforme gliosarcoma ) fail least one prior chemotherapy regimen patient receive radiation therapy . This study investigate second great line therapy recurrent grade 4 malignant glioma . The patient population include 32 patient . The patient undergo baseline magnetic resonance imaging ( MRI ) well MRI every six-week cycle determine response progression . After 16 patient recurrent GBM treat , interim analysis conduct . The common side effect associate panitumumab dermatological ( skin ) problem erythema ( redness skin ) , acneiform rash ( skin eruption face ) , skin exfoliation , pruritus ( itch ) , skin fissure ( skin tear ) , xerosis ( dryness eye , skin , mouth ) , rash . The common side effect associate irinotecan decrease blood count platelet ( increase risk bleed ) , white blood cell ( increase risk infection ) , red blood cell ( anemia ) ; diarrhea , constipation , nausea , vomit , tiredness , fever , mouth sore , dehydration ( excessive loss body fluid ) , rash , itching , change skin color , swell , numbness , tingle , dizziness , confusion , low blood pressure , sweat , hot flash , hair loss , inflammation liver , flu-like symptom , decrease urine output , shortness breath , pneumonia ( inflammatory disease lung ) .</brief_summary>
	<brief_title>Panitumumab Irinotecan Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm diagnosis primary malignant glioma ( glioblastoma multiforme gliosarcoma ) . Patients recurrent disease whose diagnostic pathology confirm grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) need rebiopsy . Age ≥ 18 year . Evidence measurable recurrent residual primary central nervous system ( CNS ) neoplasm contrastenhanced MRI An interval least 4 week prior surgical resection , major surgery require general anesthesia 1 week prior biopsy minor surgical procedure study enrollment . The subject must recover surgery related toxicity . An interval least 12 week prior radiotherapy 4 week prior monthly chemotherapy , 7 day daily chemotherapy . The lab value follow prior chemotherapy must return baseline prior study enrollment . Karnofsky ≥ 70 % . Hematocrit ≥ 29 % , absolute neutrophil count ( ANC ) ≥ 1,500 cells/μl , platelet ≥ 125,000 cells/μl . Serum creatinine ≤ 1.5 mg/dl , serum magnesium , potassium , calcium , chloride , sodium ≥ low limit normal , serum glutamicoxaloacetic transaminase ( SGOT ) bilirubin ≤ 1.5 time upper limit normal . Signed informed consent approve Institutional Review Board prior patient entry . If sexually active , patient take contraceptive measure duration treatment , 6 month afterwards . Pregnancy breast feeding Comedication may interfere study result ; e.g . immuno¬suppressive agent corticosteroid . Active infection require intravenous antibiotic . uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1 ) homozygous 7/7 genotype . Preexisting diarrhea great Grade 1 . PanitumumabSpecific Concerns : [ Subjects meet follow criterion ineligible study entry ] Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy treatment small molecule EGFr inhibitor Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result . Subject unwilling unable comply study requirement Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment . Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection ( test require absence clinical suspicion ) Patients history deep venous thrombosis , pulmonary embolism therapeutic anticoagulation . Known allergy hypersensitivity component study treatment ( ) Active infection require systemic intravenous treatment uncontrolled infection ≤14 day prior enrollment/randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Camptosar</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Duke</keyword>
	<keyword>Vredenburgh</keyword>
	<keyword>Pro00015447</keyword>
</DOC>